Schizophrenia/Psychosis

New cohort and global data link teen high-potency cannabis use to higher psychosis, bipolar, and suicide risks. Here's what psychiatrists and mental health clinicians should know in the era of legalization.

Low soluble α2δ‑1 disrupts brain excitation‑inhibition balance in schizophrenia.

New data shows stable symptoms when switching from atypical antipsychotics to Cobenfy using cross-titration.

AI video screening spots early tardive dyskinesia signs, prompting clinical follow-up and treatment.

Study links schizophrenia’s earlier onset to higher genomic deletion CNV burden, showing future potential for personalized care.

FDA expands Caplyta label to prevent schizophrenia relapse, cutting risk 63% and showing weight-neutral tolerability for sustained long-term stability.

Psychiatry experts explain why off-label psych meds and polypharmacy can be essential.

Learn how antipsychotics and stress raise prolactin, what symptoms to spot, and when to test—plus practical options to lower levels.

Faster aging may be linked to schizophrenia, according to new research.

Experts share how roluperidone provides a new opportunity in the schizophrenia treatment landscape.

New analysis links traumatic brain injury to later psychosis, prompting long-term screening and follow-up.

Explore fresh clinical insights on schizophrenia—mortality, stigma, cannabis links, lifestyle, and new treatments—and share cases for our April series.

Further data shared on LB-102 for schizophrenia.

Tazbentetol interim results show improvement in schizophrenia symptoms.

LB Pharmaceuticals has initiated the pivotal phase 3 NOVA-2 trial evaluating the efficacy and safety of LB-102 as a treatment for schizophrenia.

Discover how psychodynamic therapy and modern antipsychotics can reduce psychotic symptoms, restore meaning, and improve quality of life for patients with schizophrenia.

Can ultra-low-carb eating ease schizophrenia symptoms? Evidence suggests metabolic gains and modest mood shifts, but no cure—here’s what studies show.

Learn how to spot catatonia quickly, use BFCRS screening, and safely treat with lorazepam or ECT while preventing complications.

Early psychosis screening in teens and young adults helps catch overlooked symptoms sooner.

FDA clears Bysanti, a novel atypical antipsychotic for acute bipolar I and schizophrenia, leveraging Fanapt data; US launch planned 2026.

The FDA accepts Teva’s once-monthly olanzapine injection for schizophrenia, promising steadier adherence without mandatory 3-hour monitoring.

Explore how seizure control, antiepileptics, and surgery can trigger psychosis in epilepsy, and what guides diagnosis and treatment.

Denovo teams with Orygen to test DB103, a glutamate-targeting therapy, in a phase 2 youth trial for early psychosis.

Physical activity boosts fitness, strength, and mental health in schizophrenia, cutting cardiometabolic risk and symptoms—especially with supervised, personalized programs in care.